{"filings":[{"id":169594,"accession_number":"0001663577-25-000033","cik":1085277,"company_name":"SKINVISIBLE, INC.","ticker":"SKVI","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Skinvisible licensee Quoin reports positive Netherton Syndrome clinical results; $5M milestone payment upon approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quoin's QRX003 (using Invisicare) showed 'severe' to 'mild' improvement after 6 weeks in Netherton Syndrome studies.","FDA cleared a whole-body study at Northwestern University; no adverse events reported to date.","Clinical trials expanded to UK, Ireland, and Saudi Arabia; product licensed in 60 countries.","Skinvisible to receive $5M milestone payment plus ongoing royalties upon FDA or EU approval.","Skinvisible actively seeking partnerships for transdermal obesity therapies and other formulations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1080769.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186657,"accession_number":"0001663577-24-000257","cik":1085277,"company_name":"SKINVISIBLE, INC.","ticker":"SKVI","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Skinvisible announces 99.6% transdermal penetration of GLP-1 drug in preclinical study","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["GLP-1 drug danuglipron formulated with Invisicare showed 99.6% penetration over 6 hours in Franz cell diffusion studies.","CB-1 antagonist formulated with Invisicare showed 62% penetration over 6 hours; sustained delivery with no initial spike.","Company is developing other GLP-1 agonists and CB-1 antagonists for transdermal obesity treatment.","Seeking strategic partnerships to bring first transdermal obesity therapies to market.","Obesity drug market projected to reach $105B-$144B by 2030 per Morgan Stanley."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1080769.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219548,"accession_number":"0001663577-24-000148","cik":1085277,"company_name":"SKINVISIBLE, INC.","ticker":"SKVI","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Skinvisible issues 350,000 units at $0.10/unit in private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Each unit consists of one common share and a warrant to purchase 0.5 share at $0.20 per share.","Warrants exercisable for one year from issuance; total gross proceeds $35,000.","Securities issued to accredited investors under Section 4(2) and/or Rule 506/Regulation S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1080769.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219547,"accession_number":"0001663577-24-000143","cik":1085277,"company_name":"SKINVISIBLE, INC.","ticker":"SKVI","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Skinvisible files provisional patent for transdermal obesity drug delivery using Invisicare","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Provisional patent filed for transdermal composition of CB-1 receptor antagonists and/or GLP-1 receptor agonists.","Uses proprietary Invisicare technology; studies show up to 10x increase in transdermal delivery effectiveness.","Aims to offer needle-free alternative to injections for obesity drugs; potential to improve compliance.","Global obesity drug market projected to exceed $30B by 2027.","Company actively seeking strategic partnerships for development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1080769.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256887,"accession_number":"0001663577-23-000514","cik":1085277,"company_name":"SKINVISIBLE, INC.","ticker":"SKVI","form_type":"8-K","filed_at":"2023-10-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Skinvisible replaces auditor Gries & Associates with GreenGrowth CPAs after Gries' sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Oct 17, 2023, engaged GreenGrowth CPAs as new independent accountant; effective Oct 24, 2023 after Gries sold its business.","Gries' reports for fiscal years ended Dec 31, 2022 and 2021 had no adverse opinions but included going concern doubt.","No disagreements with Gries on accounting principles, disclosure, or audit scope during 2022, 2021, and through Oct 17, 2023.","Board of directors, acting as audit committee, approved the change; no reportable events except material weakness discussions.","Gries furnished a letter to the SEC agreeing with the company's statements, filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1080769.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384597,"accession_number":"0001663577-22-000032","cik":1085277,"company_name":"SKINVISIBLE, INC.","ticker":"SKVI","form_type":"8-K","filed_at":"2022-01-13T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Skinvisible changes auditor; Prager Metis declines reappointment over internal control issues","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prager Metis CPAs declined reappointment as auditor on Jan 7, 2022; Gries and Associates engaged Jan 12, 2022.","Former auditor's 2020 and 2019 reports included going concern uncertainty but no adverse opinions.","Reportable event: management determined internal controls over financial reporting were ineffective as of Dec 31, 2020, not remediated.","No disagreements on accounting principles or practices during 2020, 2019, and interim period through Jan 7, 2022.","Board approved new auditor; no prior consultation with Gries and Associates on accounting matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1080769.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}